Lu Ye1, Li Cai2, Yonghui Fu3, Debao Zhuang1, Xiaoqing Hu4, Youkun Jie5. 1. Department of Pathology, Jiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi, China. 2. Department of Oncology, Jiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi, China. 3. Department of Psychiatry, Jiangxi Mental Hospital/Affiliated Mental Hospital of Nanchang University, Nanchang, 330029, Jiangxi, China. 4. Department of Oncology, Jiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi, China. clez123@163.com. 5. Department of Pathology, Jiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi, China. blackwhite121@163.com.
Abstract
BACKGROUND: Venous thromboembolism (VTE) in ovarian cancer (OC) patients has been widely investigated, but our knowledge on the role of VTE in OC patients receiving chemotherapy is limited. The aim of our study was to investigate the prevalence, risk factors, and prognostic value of chemotherapy-associated VTE in OC. METHODS: Three databases (PubMed, Embase, and the Cochrane Library) were systematically searched from inception to October 14, 2020. The primary outcome was the prevalence of VTE in OC patients receiving chemotherapy. The risk factors and prognostic value of VTE were the secondary outcomes. The pooled prevalence of VTE was estimated using the generic inverse-variance method. The statistical heterogeneity was evaluated with Cochran's Q test and I2 statistic. Funnel plot, Begg's test, and Egger's test were used to assess the potential publication bias in the meta-analysis. RESULTS: A total of eleven observational studies with 4759 OC patients were included. The pooled prevalence of VTE was 9% (95% CI, 0.06-0.12) in OC patients receiving chemotherapy. The results of subgroup analysis and sensitivity analysis were basically consistent with the overall pooled estimate. Multiple significant risk factors associated with VTE were also identified including advanced age, D-dimer > 0.5 mg/mL, and tumor diameter > 10 cm. Only two included studies reported the prognostic value of VTE in OC patients receiving chemotherapy, but with inconsistent results. Funnel plot showed that there existed potential publication bias, which was further verified by statistical test, but the results of the trim-and-fill method showed the pooled estimate kept stable after adding two "missing" studies. CONCLUSIONS: This current study revealed that the pooled prevalence of chemotherapy-related VTE in OC was approximately 9% in OC patients. Risk factors for chemotherapy-related VTE were also identified which may contribute to targeting potentially preventative measures for VTE in OC.
BACKGROUND:Venous thromboembolism (VTE) in ovarian cancer (OC) patients has been widely investigated, but our knowledge on the role of VTE in OCpatients receiving chemotherapy is limited. The aim of our study was to investigate the prevalence, risk factors, and prognostic value of chemotherapy-associated VTE in OC. METHODS: Three databases (PubMed, Embase, and the Cochrane Library) were systematically searched from inception to October 14, 2020. The primary outcome was the prevalence of VTE in OCpatients receiving chemotherapy. The risk factors and prognostic value of VTE were the secondary outcomes. The pooled prevalence of VTE was estimated using the generic inverse-variance method. The statistical heterogeneity was evaluated with Cochran's Q test and I2 statistic. Funnel plot, Begg's test, and Egger's test were used to assess the potential publication bias in the meta-analysis. RESULTS: A total of eleven observational studies with 4759 OCpatients were included. The pooled prevalence of VTE was 9% (95% CI, 0.06-0.12) in OCpatients receiving chemotherapy. The results of subgroup analysis and sensitivity analysis were basically consistent with the overall pooled estimate. Multiple significant risk factors associated with VTE were also identified including advanced age, D-dimer > 0.5 mg/mL, and tumor diameter > 10 cm. Only two included studies reported the prognostic value of VTE in OCpatients receiving chemotherapy, but with inconsistent results. Funnel plot showed that there existed potential publication bias, which was further verified by statistical test, but the results of the trim-and-fill method showed the pooled estimate kept stable after adding two "missing" studies. CONCLUSIONS: This current study revealed that the pooled prevalence of chemotherapy-related VTE in OC was approximately 9% in OCpatients. Risk factors for chemotherapy-related VTE were also identified which may contribute to targeting potentially preventative measures for VTE in OC.
Authors: Simon F Stämpfli; Alexander Akhmedov; Cathérine Gebhard; Christine Lohmann; Erik W Holy; Izabela Rozenberg; Remo Spescha; Yi Shi; Thomas F Lüscher; Felix C Tanner; Giovanni G Camici Journal: Arterioscler Thromb Vasc Biol Date: 2010-08-05 Impact factor: 8.311
Authors: Julia Rose Salinaro; Kourtnie McQuillen; Megan Stemple; Robert Boccaccio; Jessie Ehrisman; Amelia M Lorenzo; Laura Havrilesky; Angeles Alvarez Secord; Valerie Galvan Turner; Kathleen Nadine Moore; Brittany Davidson Journal: Int J Gynecol Cancer Date: 2020-02-12 Impact factor: 3.437
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: Keattiyoat Wattanakit; Pamela L Lutsey; Elizabeth J Bell; Heather Gornik; Mary Cushman; Susan R Heckbert; Wayne D Rosamond; Aaron R Folsom Journal: Thromb Haemost Date: 2012-07-10 Impact factor: 5.249